Mini Review
Analysis Reimbursement & Public Spending Polices for Immunological Diseases at Law and Middle Income Countries
Abdalla Abotaleb*
WHO Project Manager, Health Care Reforming Expert, Egypt
Received Date: 12/06/2020; Published Date: 06/07/2020
*Corresponding author: Abdalla Abotaleb, WHO Project Manager, Health Care Reforming Expert, Egypt
DOI: 10.46718/JBGSR.2020.02.000052
Cite this article: Abdalla Abotaleb, Analysis Reimbursement & Public Spending Polices for Immunological Diseases at Law and Middle Income Countries. Op Acc J Bio Sci & Res 2(5)-2020.
Abstract
Selecting the right patient for the right treatment with efficient cost is the main goal for effective health system
Immunological diseases specially (ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, psoriasis)
Are characterized with significant impact on quality of life, mobility young age groups chronicity and of course high cost of treatment especially with new innovative treatments like Biological products and others. The main objectives for this research is analysis of reimbursement & public spending polices for immunological diseases at law and middle income countries. Including (Egypt, Algeria, Morocco, Jordan, Kenia, Iraq, Turkey)
Methods: Integration between A systematic literature reviews & analysis for Local guidelines.
Interviews was conducted with Key stock holders for health system in previous countries those stock holders included physicians, clinical pharmacist, Representors of patient's groups, payers, service providers using questionnaire as a survey tool for interview. Public expenditures descriptive analysis for previous diseases was conducted.
Results: The analysis founded that conducting & implementation of guidelines based on minimizing expenditures ( 70 % of cases ) price for treatment playing major role for selection ( 74 % of cases ) clinical significance and differences for innovative products was absent for stockholders concept ( 60 % ) relapse rates . Modifications of disease pattern was increased (51 % of cases) public expenditures was increased significantly at 45 % including( consequences for treatment frailer, disability & low quality of life ) of cases of cases not a result for number of patients, quality of life was decreased with 52 % of cases. Reimbursement & public spending polices for immunological diseases need effective reforming this reforming must take into considerations the following concepts (clinical values, Economic values .quality of life).
Conclusion: Reimbursement & public spending polices for immunological diseases need effective reforming this reforming must take into considerations the following concepts (clinical values, Economic values .quality of life)
Introduction
Selecting the right patient for the right treatment with efficient cost is the main goal for effective health system Immunological diseases specially (ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, psoriasis). Are characterized with significant impact on quality of life, mobility young age groups chronicity and of course high cost of treatment especially with new innovative treatments like Biological products and others. The main objectives for this research is analysis of reimbursement & public spending polices for immunological diseases at law and middle income countries. Including (Egypt, Algeria, Morocco, Jordan, Kenia, Iraq, Turkey) (Figure 1-7).
Figure 1: The net % increase/year of the incidence and prevalence of autoimmune diseases worldwide.
Figure 2: (A): The net % year increases of diseases categories. (B): The Table below is detailing the different diseases and countries surveyed.
Figure 3: The Geoepideomolgy of the net increase % Year of autoimmune diseases.
Figure 4: Incidence and prevalence and correlations with YLDs.
Figure 5: Data Validity Analysis.
Figure 6: Data Validity Analysis.
Figure 7: Treatment Analysis.
Materials and Methods
Integration between A systematic literature reviews & analysis for Local guidelines. Interviews was conducted with Key stock holders for health system in previous countries those stock holders included physicians, clinical pharmacist, Representors of patient's groups, payers, service providers using questionnaire as a survey tool for interview. Public expenditures descriptive analysis for previous diseases was conducted [1-8].
Discussion
This study are trying to find an answer about how health policy for immunological diseases are developed and impact of efficient treatment polices on patients outcomes plus public spending.
Results
The analysis founded that conducting & implementation of guidelines based on minimizing expenditures (70% of cases) price for treatment playing major role for selection ( 74% of cases) clinical significance and differences for innovative products was absent for stockholders concept ( 60 % ) relapse rates . Modifications of disease pattern was increased (51% of cases) public expenditures was increased significantly at 45 % including( consequences for treatment frailer, disability & low quality of life) of cases of cases not a result for number of patients, quality of life was decreased with 52 % of cases.
Egypt
The analysis founded that conducting & implementation of guidelines based on minimizing expenditures (77 % of cases) price for treatment playing major role for selection (85% of cases) clinical significance and differences for innovative products was absent for stockholders concept (71%) relapse rates . Modifications of disease pattern was increased (61% of cases) public expenditures was increased significantly at 51 % including( consequences for treatment frailer, disability & low quality of life) of cases of cases not a result for number of patients, quality of life was decreased with 61 % of cases.
Conclusion
Reimbursement & public spending polices for immunological diseases need effective reforming this reforming must take into considerations the following concepts (clinical values, Economic values .quality of life).
References
7. Lerner A, Matthias T (2015) Increased knowledge and awareness of celiac disease will benefit the elderly. Intern J of Celiac Dis 3: 112-114.
8. GBD (2017) Disease and Injury Incidence and Prevalence Collaborators. Lancet 392: 1789-858.
Recent Comments